AstraZeneca to present pivotal roxadustat Phase III data at the American Society of Nephrology Kidney Week 2019
Pooled efficacy and cardiovascular safety analyses from global Phase III programme, and efficacy data from Phase III OLYMPUS and ROCKIES trials to be presented Unprecedented 41 abstracts from the AstraZeneca renal portfolio and pipeline demonstrate commitment to advancing careAstraZeneca will present pooled efficacy and cardiovascular safety analyses from the Phase III clinical programme of roxadustat for the treatment of anaemia from chronic kidney disease (CKD) in non dialysis-dependent (NDD) or dialysis-dependent (DD) patients. The data are among an unprecedented 41 AstraZeneca